Compare · LH vs MTAC
LH vs MTAC
Side-by-side comparison of Labcorp Holdings Inc. (LH) and MedTech Acquisition Corporation (MTAC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LH and MTAC operate in Medical Specialities (Health Care), so they compete in similar markets.
- LH is the larger of the two at $21.68B, about 70.2x MTAC ($308.8M).
- LH has hit the wire 7 times in the past 4 weeks while MTAC has been quiet.
- LH has more recent analyst coverage (25 ratings vs 0 for MTAC).
- Company
- Labcorp Holdings Inc.
- MedTech Acquisition Corporation
- Price
- $263.82-0.44%
- $11.67+15.43%
- Market cap
- $21.68B
- $308.8M
- 1M return
- -0.86%
- -
- 1Y return
- +14.64%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 7
- 0
- Recent ratings
- 25
- 0
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
MedTech Acquisition Corporation
MedTech Acquisition Corporation does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.
Latest LH
- Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®
- Labcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 Minutes
- Labcorp Introduces AI-Powered Real-World Data Platform with AWS and Datavant to Accelerate Alzheimer's Research
- SEC Form DEFA14A filed by Labcorp Holdings Inc.
- SEC Form DEF 14A filed by Labcorp Holdings Inc.
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp Declares Quarterly Dividend
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp to Announce First Quarter Financial Results on April 30, 2026
- SEC Form 4 filed by Schechter Adam H
Latest MTAC
- Szela Mary T was granted 84,899 shares, increasing direct ownership by 30% to 364,862 units (SEC Form 4)
- Marshak Richard was granted 14,752 shares, increasing direct ownership by 118% to 27,251 units (SEC Form 4)
- Cox Bryan F. was granted 14,752 shares, increasing direct ownership by 21% to 86,696 units (SEC Form 4)
- Stevens Jennifer was granted 14,752 shares, increasing direct ownership by 82% to 32,783 units (SEC Form 4)
- Devlin Jodi was granted 17,500 shares (SEC Form 4)
- Murphy Sean was granted 34,144 shares, increasing direct ownership by 205% to 50,788 units (SEC Form 4)
- Katz Steven C was granted 34,144 shares, increasing direct ownership by 99% to 68,587 units (SEC Form 4)
- SEC Form 4 filed by Murphy Sean
- SEC Form 4 filed by Marshak Richard
- SEC Form 424B3 filed by MedTech Acquisition Corporation